Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study
ConclusionsOnce-daily IND 75 μg and IND 150 μg via Breezhaler® in combination with background ICS therapy provided substantial bronchodilation in children with asthma and were well tolerated. Taken together, these clinical and systemic exposure findings support IND 75 μg as the most appropriate dose for evaluation in Phase III trials in combination with MF in pediatric asthma.Trial RegistrationClinicalTrials.gov (NCT02892019; 08-Sep-2016). (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 8, 2023 Category: Drugs & Pharmacology Source Type: research
Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment
ConclusionsPatients exhibiting symptoms of rhinitis may receive nasal esketamine spray without dose adjustment. In addition, esketamine may be administered 1 h after using a nasal decongestant or corticosteroid.Trial RegistrationThe study was registered in the Clinical Trials (NCT02154334) and EudraCT (2014 ‐000534‐38) registries. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - July 4, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy of Normal Saline Nasal Spray Added to Standard Treatment Regimen of Chronic Rhinosinusitis: A Randomised Controlled Trial
AbstractChronic Rhinosinusitis is characterized by inflammation of lining of nose and paranasal sinuses leading to nasal blockage/discharge, facial pressure/pain and loss of smell sensation, generally treated with medical therapy initially. Nasal saline irrigation is one of the treatment modalities commonly used to improve symptoms. The aim was to evaluate efficacy of adding normal saline nasal spray to standard treatment regimen of chronic rhinosinusitis. A randomized, controlled, single blinded study with 40 chronic rhinosinusitis patients. Study group was prescribed Normal Saline nasal spray (1 puff in each nostril, thr...
Source: Indian Journal of Otolaryngology and Head and Neck Surgery - June 28, 2023 Category: ENT & OMF Source Type: research
Topical corticosteroids for the prevention of severe radiation dermatitis: a systematic review and meta-analysis
ConclusionsThe current evidence supports the use of TCs in preventing severe reactions of RD. Both MF and betamethasone were found to be effective; however, betamethasone, a higher potency TC, is more effective despite MF being more commonly reported in literature. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - June 6, 2023 Category: Cancer & Oncology Source Type: research
Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis
No evidence shows that one intranasal corticosteroid (INCS) is better than another for treating moderate-to-severe allergic rhinitis (AR). This network meta-analysis assessed the comparative efficacy and acceptability of licensed dose aqueous INCSs. PubMed/MEDLINE, Scopus, EMBASE, and the Cochrane Central Register of Controlled Trials were searched until 31 March 2022. Eligible studies included randomized controlled trials comparing INCSs with placebo or other types of INCSs in patients with moderate-to-severe allergic rhinitis. Two reviewers independently screened and extracted data following the Preferred Reporting Items...
Source: Frontiers in Pharmacology - May 23, 2023 Category: Drugs & Pharmacology Source Type: research
Zein nanoparticles as oral carrier for mometasone furoate delivery
Drug Deliv Transl Res. 2023 May 19. doi: 10.1007/s13346-023-01367-y. Online ahead of print.ABSTRACTMometasone furoate (MF) is a synthetic glucocorticoid used clinically to treat specific inflammatory disorders including superior and inferior respiratory tract. Due to its poor bioavailability we further investigated whether nanoparticles (NPs) made of zein protein may constitute a safe and effective choice to incorporate MF. Thus, in this work, we loaded MF into zein NPs aiming to evaluate possible advantages that could result from oral delivery and extend the range of MF application such as inflammatory gut diseases. MF-lo...
Source: Cell Research - May 19, 2023 Category: Cytology Authors: Priscila Zimath Soraia Pinto Sofia Dias Alex Rafacho Bruno Sarmento Source Type: research
The Rising Cost of Rhinologic Medications
CONCLUSION: The rising cost of highly utilized medications contribute to increased patient acquisition costs and may pose barriers of drug adherence to particularly vulnerable populations.PMID:37098404 | DOI:10.1016/j.anai.2023.04.013 (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - April 25, 2023 Category: Allergy & Immunology Authors: Milind Vasudev Sina J Torabi Lauren Michelle Leo L T Meller Jack L Birkenbeuel Kelsey M Roman Theodore V Nguyen Edward C Kuan Source Type: research
The Rising Cost of Rhinologic Medications
CONCLUSION: The rising cost of highly utilized medications contribute to increased patient acquisition costs and may pose barriers of drug adherence to particularly vulnerable populations.PMID:37098404 | DOI:10.1016/j.anai.2023.04.013 (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - April 25, 2023 Category: Allergy & Immunology Authors: Milind Vasudev Sina J Torabi Lauren Michelle Leo L T Meller Jack L Birkenbeuel Kelsey M Roman Theodore V Nguyen Edward C Kuan Source Type: research
Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/mometasone furoate
Expert Rev Clin Immunol. 2023 Apr 11. doi: 10.1080/1744666X.2023.2200165. Online ahead of print.ABSTRACTINTRODUCTION: Allergic rhinitis (AR) is a common disease with an important impact on the quality of life and very high management costs. In many patients, the poor control of rhinitis symptoms often requires the use of different drugs, and polytherapy tends to reduce therapeutic adherence. According to the latest version of ARIA guidelines, the currently recommended drugs for the treatment of moderate to severe AR are second-generation anti-histamines, intranasal corticosteroids, and their combination, even in a single n...
Source: Expert Review of Clinical Immunology - April 11, 2023 Category: Allergy & Immunology Authors: Erminia Ridolo Alessandro Barone Francesca Nicoletta Giovanni Paoletti Enrico Hefler Luca Malvezzi Giorgio Walter Canonica Source Type: research
Physalis alkekengi L. var. franchetii combined with hormone therapy for atopic dermatitis
In this study, a 2,4-dinitrochlorobenzene-induced AD BALB/c mouse model was established, and a comprehensive pharmacological method was used to determine the pharmacological effects and molecular mechanisms of PAF in the treatment of AD. The results indicated that both PAF gel (PAFG) and PAFG+MF (mometasone furoate) attenuated the severity of AD and reduced the infiltration of eosinophils and mast cells in the skin. Serum metabolomics showed that PAFG combined with MF administration exerted a synergistic effect by remodeling metabolic disorders in mice. In addition, PAFG also alleviated the side effects of thymic atrophy a...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 1, 2023 Category: Drugs & Pharmacology Authors: Mengru Yang Mantong Zhao Tianyi Xia Ying Chen Wei Li Han Zhang Mingming Peng Chuanqiu Li Xia Cao Lanyuan Liang Yimin Yue Luyang Zhong Jieyong Du Jianhua Li Yi Wang Zunpeng Shu Source Type: research
Physalis alkekengi L. var. franchetii combined with hormone therapy for atopic dermatitis
In this study, a 2,4-dinitrochlorobenzene-induced AD BALB/c mouse model was established, and a comprehensive pharmacological method was used to determine the pharmacological effects and molecular mechanisms of PAF in the treatment of AD. The results indicated that both PAF gel (PAFG) and PAFG+MF (mometasone furoate) attenuated the severity of AD and reduced the infiltration of eosinophils and mast cells in the skin. Serum metabolomics showed that PAFG combined with MF administration exerted a synergistic effect by remodeling metabolic disorders in mice. In addition, PAFG also alleviated the side effects of thymic atrophy a...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 1, 2023 Category: Drugs & Pharmacology Authors: Mengru Yang Mantong Zhao Tianyi Xia Ying Chen Wei Li Han Zhang Mingming Peng Chuanqiu Li Xia Cao Lanyuan Liang Yimin Yue Luyang Zhong Jieyong Du Jianhua Li Yi Wang Zunpeng Shu Source Type: research
Mometasone Furoate Use for Recurrent Adenoid Hypertrophy: Randomized Controlled Clinical Trial
Conclusion: Mometasone furoate can temporarily reduce the adenoid size, reducing symptoms related to adenoid hypertrophy. (Source: Indian Journal of Otolaryngology and Head and Neck Surgery)
Source: Indian Journal of Otolaryngology and Head and Neck Surgery - March 23, 2023 Category: ENT & OMF Source Type: research
Oral mometasone furoate administration preserves anti-inflammatory action with fewer metabolic adverse effects in rats
CONCLUSION: MF maintains anti-inflammatory activity when administered by systemic routes and exerts less impact on metabolism when administered orally in male and female rats, effects that are GR-dependent and reversible. Category: Metabolic Disorders and Endocrinology.PMID:36893817 | DOI:10.1016/j.bcp.2023.115486 (Source: Biochemical Pharmacology)
Source: Biochemical Pharmacology - March 9, 2023 Category: Drugs & Pharmacology Authors: Priscila L Zimath Milena S Almeida Maciel A Bruxel Alex Rafacho Source Type: research
